Phase I Study to Compare the Pharmacokinetics of Budesonide and Formoterol Delivered With Symbicort Aerosphere® and Symbicort® pMDI in Children 4 to Less Than 12 Years of Age With Asthma

The purpose of this study is to assess the pharmacokinetics (PK) and safety of symbicort aerosphere and symbicort pressurized metered dose inhaler (pMDI) in participants with asthma aged 4 to less than 12 years.

开始日期2026-03-05

申办/合作机构

AstraZeneca PLC

CTR20260268

/ Recruiting临床3期

布地奈德福莫特罗吸入粉雾剂（II）治疗成人哮喘有效性和安全性的多中心、随机、双盲双模拟、阳性药物平行对照临床研究

主要目的：以AstraZeneca AB（阿斯利康）生产的布地奈德福莫特罗吸入粉雾剂（II）（Symbicort Turbuhaler，信必可都保）为阳性对照药品，评价山东京卫制药有限公司生产的布地奈德福莫特罗吸入粉雾剂（II）用于治疗成人支气管哮喘的有效性非劣于阳性对照药品。次要目的：评价布地奈德福莫特罗吸入粉雾剂（II）用于治疗成人支气管哮喘的安全性。

开始日期2026-03-04

申办/合作机构

山东京卫制药有限公司

NCT07352488

/ Not yet recruitingN/AIIT

Effect of Modified Shenling Baizhu Powder on Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome: A Multicenter, Randomized Controlled Trial

Allergic asthma is a common allergic disease characterized by a protracted disease course and recurrent episodes, which severely impairs patients' physical and mental health. There is a paucity of high-quality clinical evidence in the treatment of allergic asthma with traditional Chinese medicine (TCM). This study will enroll patients who are persistent allergic asthma with spleen deficiency and dampness accumulation syndrome. A multicenter, randomized, double-blind, placebo-controlled trial design is adopted. The experimental group will receive Modified Shenling Baizhu Powder in addition to Budesonide and Formoterol Fumarate Powder for Inhalation, while the control group will receive a placebo in addition to the same inhalation therapy. Both groups will undergo an 8 week of treatment followed by a 12 week of follow-up. The primary outcome is Asthma Control Test scores, and the secondary outcomes include acute exacerbations, Asthma Control Questionnaire scores, Asthma Quality of Life Questionnaire scores, pulmonary function, airway inflammatory markers, clinical symptom scores, serum inflammatory markers, immune markers, and use of controller medications.

开始日期2026-01-15

申办/合作机构

河南中医药大学

100 项与布地奈德福莫特罗相关的临床结果

登录后查看更多信息

100 项与布地奈德福莫特罗相关的转化医学

登录后查看更多信息

100 项与布地奈德福莫特罗相关的专利（医药）

登录后查看更多信息

486

项与布地奈德福莫特罗相关的文献（医药）

2026-04-01·Lancet Respiratory Medicine

Budesonide–glycopyrronium–formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials

Article

作者: Bondoc, Marco ; Springer, Katarzyna ; Shah, Mihir ; Jackson, David J ; Papi, Alberto ; Obasi, Chidi ; Helman, Jesse ; Wise, Robert A ; Bowen, Karin ; Patel, Mehul ; Salter, Patricia ; Movitz, Charlotta ; Chen, Ruchong ; Lugogo, Njira ; Pandya, Hitesh ; Megally, Ayman ; Trasieva, Teodora ; Knappenberger, Katharine

BACKGROUND:

Long-acting muscarinic antagonists (LAMA) can be added to inhaled corticosteroid- (ICS)-long-acting β₂-agonist (LABA) therapy for inadequately controlled asthma. We aimed to evaluate the efficacy and safety of budesonide-glycopyrronium-formoterol fumarate dihydrate (BGF) versus budesonide-formoterol fumarate dihydrate using Aerosphere co-suspension delivery technology (BFF_A) and the current suspension formulation (Symbicort, BFF_S).

METHODS:

Two multicentre, randomised, double-blind, double-dummy, phase 3 studies (KALOS and LOGOS) recruited participants aged 12-80 years with inadequately-controlled asthma despite daily medium-dose or high-dose ICS-LABA use from across 378 sites in 20 countries (KALOS), and 324 sites in 15 countries (LOGOS). Participants were randomly assigned (1:1:1:1) to BGF 320 μg, 28·8 μg, 10 μg (BGF 28·8); BGF 320 μg, 14·4 μg, 10 μg (BGF 14·4); BFF_A 320 μg, 10 μg; or BFF_S 320 μg, 9 μg, twice a day via pressurised metered-dose inhaler for 24-52 weeks. Primary lung function endpoints were change from baseline in FEV₁ area under the curve from 0 h to 3 h (AUC_0-3) and in morning pre-dose trough FEV₁ from day 1 to week 24 (over 24 weeks; depending on regional health authority guidance). The primary pooled analysis across both studies was annualised severe exacerbations. The efficacy analysis set and safety set included all randomly assigned participants receiving any amount of study treatment but were analysed according to randomly assigned treatment and received treatment, respectively. The KALOS and LOGOS studies are registered with ClinicalTrials.gov (NCT04609878 and NCT04609904, respectively) and are complete.

FINDINGS:

Between Dec 15, 2020, and March 21, 2025 (KALOS), and between March 1, 2021, and March 20, 2025 (LOGOS), 8820 participants were recruited and 4311 received treatment (1179 received BGF 28·8, 726 received BGF 14·4, 1210 received BFF_A, and 1196 received BFF_S). In each study, the pre-specified multiplicity-adjusted primary endpoints for all regulatory comparisons were met. Least squares mean differences favoured BGF 28·8 for change from baseline in trough FEV₁ and FEV₁ AUC_0-3 across all comparisons (all p<0·05). Least squares mean differences in change from baseline in morning pre-dose trough FEV₁ and in FEV₁ AUC_0-3 over 24 weeks for BGF 28·8 versus BFF_combined were 76 mL (95% CI 57-94; p<0·0001) and 90 mL (72-108; p<0·0001), respectively. BGF 28·8 reduced severe exacerbation rates versus BFF_combined (incidence rate ratio 0·86, 95% CI 0·76-0·97; p=0·012) and versus BFF_S (0·82, 0·71-0·94; p=0·0043). Exacerbation rate ratio for BGF 28·8 versus BFF_A was 0·90 (95% CI 0·78-1·03; p=0·12). 627 (53·2%) adverse events were observed with BGF 28·8, 436 (60·0%) with BGF 14·4, 666 (55·2%) with BFF_A, and 698 (58·4%) with BFF_S. No deaths were treatment related.

INTERPRETATION:

These findings show that BGF improves lung function and reduces severe exacerbation rates in a broad population with asthma inadequately controlled despite medium-dose or high-dose ICS-LABA use. Given that these findings were observed regardless of recent exacerbation history, BGF could benefit individuals with inadequately controlled asthma without requiring a recent episode of acute deterioration on ICS-LABA before escalation.

FUNDING:

AstraZeneca.

2026-04-01·JOURNAL OF ETHNOPHARMACOLOGY

Bufei formula attenuates airway mucus hypersecretion in COPD through inhibition of TRIM56-mediated ITGB4 ubiquitination

Article

作者: Zhang, Qin ; Cheng, Mengmeng ; Wei, Yanxin ; Zhao, Di ; Xin, Nan ; Zhao, Peng ; Li, Jiansheng ; Zhang, Zeyu

ETHNOPHARMACOLOGICAL RELEVANCE:

Bufei Formula (BFF), a traditional Chinese medicine, has been widely utilized in the clinical treatment of chronic obstructive pulmonary disease (COPD), though its underlying mechanisms remain unclear and warrant further investigation.

AIM OF THE STUDY:

To investigate the mechanisms by which BFF alleviates COPD airway mucus hypersecretion through the TRIM56-mediated ubiquitination.

MATERIALS AND METHODS:

A cigarette smoke-induced COPD mouse and cigarette smoke extract (CSE)-induced airway epithelial cells were established to evaluate the effect of BFF on airway mucus hypersecretion. The target protein of BFF was identified using DARTS technology. Co-immunoprecipitation (Co-IP) combined with mass spectrometry (MS) was used to identify the downstream proteins of TRIM56.

RESULTS:

BFF can effectively improve lung function and pathological changes, and inhibit inflammation in COPD mice, as well as downregulate the levels of mucin and MUC5AC in the lung. BFF-4, an active fraction derived from BFF, directly inhibits the expression of MUC5AC and TNF-α induced by CSE in epithelial cells. DARTS analysis and single-cell sequencing analysis revealed that TRIM56 is a target of BFF-4, and its mediated ubiquitination contributes to the effects of BFF-4. Moreover, high levels of TRIM56 and ubiquitinated proteins are expressed both in vivo and in vitro. BFF-4 significantly downregulates these expressions. Furthermore, overexpression of TRIM56 and ubiquitinated proteins markedly diminishes the inhibitory effect of BFF-4 on mucin expression. Overexpression of TRIM56 also counteracts the inhibition of ubiquitination by BFF-4. Co-IP-MS analysis revealed that TRIM56 binds to ITGB4, which in turn regulates the expression of MUC5AC. Furthermore, molecular docking identified the top five small molecules with the highest affinity for TRIM56 were identified, suggesting their potential for direct interaction with TRIM56.

CONCLUSION:

BFF-4 effectively ameliorates airway mucus hypersecretion in COPD by inhibiting TRIM56-mediated downregulation of protein ubiquitination, including ITGB4.

2026-03-01·CLINICAL THERAPEUTICS

Safety Assessment of Budesonide/Formoterol: Real-World Pharmacovigilance Analysis Using the FAERS, JADER, and CVAR Databases

Article

作者: Zou, Fan ; Chen, Zhenyong ; Zhu, Chengyu ; Lan, Yuanbo ; Cui, Zhiwei

BACKGROUND:

Asthma and chronic obstructive pulmonary disease are common respiratory disorders with significant global health implications. Budesonide/formoterol (Symbicort) is a fixed-dose inhaler combining budesonide and formoterol fumarate dihydrate, widely used for disease management. While its clinical efficacy is well established, there is an increasing number of adverse drug event (ADE) reports, highlighting the need for thorough real-world safety evaluations.

METHODS:

We performed a retrospective pharmacovigilance study using three major spontaneous reporting systems: the US Food and Drug Administration Adverse Event Reporting System (FAERS), the Japanese Adverse Drug Event Report (JADER), and the Canada Vigilance Adverse Reaction Database (CVARD). We used multiple disproportionality algorithms, including reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker for signal detection. Additionally, subgroup and sensitivity, along with logistic regression, were performed. Weibull distribution and log-rank testing were used to assess event timing.

RESULTS:

A total of 30,689 ADEs were identified in FAERS, spanning 27 system organ classes. Expected signals such as cough, dysphonia, and bronchitis were confirmed. Unexpected events included dyspnea, visual and memory impairment, coronary artery embolism, and asthmatic crisis. Sex-stratified analysis revealed female-specific risks (eg, malaise, bronchitis, alopecia, weight gain) and male-specific risks (eg, dysuria, myocardial infarction). Younger patients (<18 years) were at higher risk for asthmatic crisis, whereas older patients (>65 years) showed a protective effect. The median onset of ADEs was 55 days. Distinctive signals emerged from JADER (eg, pneumonia, liver injury) and CVARD (eg, hemoptysis, hypothyroidism).

CONCLUSIONS:

This multi-database analysis highlights the need for continuous pharmacovigilance for budesonide/formoterol. The identification of novel ADE signals emphasizes the importance of vigilant monitoring, especially during early treatment, to enhance safety and therapeutic outcomes.

315

项与布地奈德福莫特罗相关的新闻（医药）

2026-04-28

·今日头条

动态 | 8.5亿美元！杭州经开区天境生物拿下国际巨头“大单”

近日，天境生物药业（杭州）股份有限公司（以下简称天境生物）的核心产品CD38单克隆抗体菲泽妥单抗在中国区的开发与商业化权益，与全球生物制药巨头渤健达成战略合作。根据协议，天境生物将获得1亿美元首付款，以及最高7.5亿美元的潜在里程碑付款，交易总金额达8.5亿美元，并可获得最高两位数的销售分成。这不是一次简单的权益转让。8.5亿美元的背后，是国际巨头对中国药企研发能力的深度认可，也是杭州经开区生物医药产业从“跟跑”到“并跑”的生动注脚。菲泽妥单抗“大显身手” 有望成为国内首款地产多发性骨髓瘤“利器” 天境生物成立于2019年，总部位于杭州医药港，是一家聚焦于自身免疫疾病、肿瘤免疫和代谢疾病等领域创新疗法的全链条生物科技公司。公司立足中国，已建成涵盖上海、北京研发中心和杭州GMP生产基地在内的产业链闭环。本次合作的核心亮点在于实现了菲泽妥单抗全球权益的统一。早在2024年7月，渤健即以18亿美元收购HI-Bio（注：一家美国生物公司），获得了该产品在大中华区以外的全球开发与商业化权益。此次与天境生物携手，填补了其在中国市场的权益空白。中国区8.5亿美元的交易价值，在该产品的全球布局中占据重要地位。菲泽妥单抗是一款靶向CD38的人源单克隆抗体，能够精准清除致病的CD38阳性浆细胞，从根源上改善自身免疫性疾病病程。CD38是多发性骨髓瘤的关键靶点，该病以老年人群为主，治疗难度大、易复发且用药负担重。2024年12月，其治疗多发性骨髓瘤的上市申请已获受理，目前处于审评阶段，有望成为国内首款地产CD38抗体药物。值得一提的是，天境生物位于钱塘的GMP标准生产基地已取得药品生产许可证，可实现菲泽妥单抗等核心产品的本土化稳定供应。在此次合作中，天境生物保留了该产品的本地化生产权益，既能获得稳健的现金流，也能通过销售分成分享长期收益。对患者来说，未来该产品实现本地化规模化生产后，有望在保证药效与安全性的同时提升可及性，降低患者长期用药负担。本次交易是天境生物加速从研发型公司向全产业链药企转型的缩影。此前，天境生物先后与韩国ABL Bio、石药集团、济川药业、赛诺菲等企业达成合作，将多款产品的部分权益授权给专业伙伴，既获得资金支持，也借助伙伴优势加速产品落地，持续优化资源配置。目前，天境生物已成功构建了具有差异化优势的多梯队临床产品管线和临床前管线。第一梯队中，菲泽妥单抗和依坦生长激素α两款产品已进入产品上市受理阶段，另外三款创新产品预计于2025年进入三期临床阶段，预计2026至2027年将迎来密集的商业化收获期。第二梯队则聚焦新一代创新药，依托自有技术平台布局双抗、三抗等产品，已陆续进入临床阶段。杭州经开区生态持续赋能生物医药产业加速崛起天境生物与渤健达成合作并非孤例。在钱塘，类似的“强强联手”正在密集上演。此前，同样位于杭州医药港的畅溪制药，就旗下吸入粉雾剂产品CXG87与华东医药达成中国大陆独家商业化合作。更引人注目的是，今年2月，先为达生物与全球制药巨头辉瑞中国签署战略协议，辉瑞获得其新一代GLP-1受体激动剂埃诺格鲁肽注射液在中国大陆的独家商业化权益，迈出其在全球代谢领域战略布局的第一步，先为达生物将获得最高可达4.95亿美元的付款总额。天境生物、畅溪制药、先为达生物——三家企业同属钱塘，同样将核心产品的商业化权益授权给国内外头部药企，这并非偶然。其背后，离不开钱塘优质的生物医药产业生态赋能。 “生物医药研发需要大量资金，我们每年投入近5亿元。”正如天境生物相关负责人所说，从早期融资阶段开始，和达金服、杭实集团、钱塘城发等政府背景平台就以市场化方式参与进来，“这类‘耐心资本’不追求短期回报，而是陪伴企业穿越创新周期。” 作为全省生物医药产业核心平台，杭州医药港目前已集聚生物医药企业1800余家，培育上市及拟上市企业27家，累计138个创新药进入临床试验阶段，目前有4款创新药处于上市审批阶段。1类创新药“年年有钱塘造”的愿景，正在这里变成现实。从“单点突破”到“群体崛起”，钱塘生物医药产业正以密集的“强强联手”证明：这片创新沃土，已具备参与全球竞争的实力与底气，而钱塘，愿用“耐心资本”浇灌创新沃土，让更多本土药企站上全球舞台中央。

2026-04-28

·新浪看点

新浪科学热点小时报丨2026年04月28日08时_今日实时科学热点速递

1、美媒：“液体齿轮”，没齿也能转（来源：环球网资讯）来源：环球时报美国“每日科技”网站4月23日文章，原题：科学家创造出无需接触即可旋转的“液体齿轮” 近日，美国纽约大学和中国上海纽约大学的研究人员在美国《物理评论快报》上发表论文，展示了一种液体齿轮系统，利用流体运动产生旋转，有望催生出比传统齿轮更具适应性和耐用性的机械装置。齿轮作为机械的基本组成部分已有数千年历史，最早的齿轮可以追溯到几千年前的中国，当时人们用齿轮制造战车，驰骋于戈壁沙漠。几个世纪以来，齿轮在各种装置中都发挥着重要作用。尽管传统齿轮历史悠久，但它们也存在局限性。http://k.sina.com.cn/article_5952915720_162d2490806703supq.html2、脑机接口“狂飙”！120亿元大市场，来了→脑机接口是指通过在脑与机器之间建立信息通道，实现生物智能与机器智能的协同交互，是生命科学和信息科学融合发展的前沿技术。中国信息通信研究院预测，2025年我国脑机接口市场规模约为30亿元，2030年预计达到120亿元。2026年，脑机接口首次写入政府工作报告，被明确为培育发展的六大未来产业之一。如今这项让大脑与外部设备直接“对话”的技术，正加速在医疗康复、健康监测乃至日常生活的多元化场景应用落地。从神经康复到感官重建脑机接口医疗应用场景加速落地在首都医科大学附属北京天坛医院，全国首个脑机接口咨询评估门诊已经运行一年多。http://finance.sina.com.cn/wm/2026-04-28/doc-inhvyzkp1819139.shtml3、国际首套单边锚智能自动观测浮标完成布放我国研制的单边锚智能自动观测浮标。本报讯（记者廖洋通讯员王敏）近日，中国科学院海洋研究所自主研制的直径6米圆盘型单边锚智能自动观测浮标在山东荣成海域完成布放，并正式运行。这是国际首套采用圆盘型单边锚结构设计的综合观测浮标系统，其布放和应用填补了我国近海面向全水层智能观测能力的技术空白。中国科学院海洋研究所观测网络中心总工程师刘长华介绍，该浮标系统突破了传统圆盘型浮标中心单点系泊结构形式，通过优化配载和多功能区浮力舱设计，提升浮标稳性，降低了海上施工难度，减少了海上作业风险。http://finance.sina.com.cn/tech/roll/2026-04-28/doc-inhvyzks7398296.shtml4、科学家为磁性分类建立统一对称性框架研究示意图。本报讯（记者刁雯蕙）南方科技大学物理系、量子功能材料全国重点实验室教授刘奇航团队，在对称性分类磁性的基础理论研究中取得进展。相关成果近日发表于《自然》。磁性是凝聚态物理重要的研究领域之一，在信息存储、自旋电子学及量子材料研究中具有广阔应用前景。根据系统是否显示宏观磁化，磁有序结构通常被划分为铁磁性和反铁磁性两大类。过去几十年来，物理学界主要依赖磁空间群框架来描述磁性材料的对称性，而磁空间群操作要求自旋与晶格旋转保持一致，导致它无法完整描述磁序的几何特性。如何从数学方面严格界定铁磁性与反铁磁性的边界？研究团队采用自旋空间群框架对磁性进行划分。http://finance.sina.com.cn/tech/roll/2026-04-28/doc-inhvyzkq8608751.shtml5、我国首个百万方级盐穴储氢工程投产工程现场。本报讯（记者李思辉通讯员段金利）4月25日，我国首个百万方级盐穴储氢示范工程在河南省平顶山市投产运行。该项目的落地投用补齐了氢能大规模、低成本储能关键短板，标志着我国氢能“制-储-输-用”正式迈入产业化新阶段。该工程由中国科学院武汉岩土力学研究所（以下简称武汉岩土所）与中国平煤神马集团共同实施。中国工程院院士、武汉岩土所研究员杨春和团队通过精细化选址选层方法，精准确定1418米钻井深度，主导建成水溶体积超3万方的盐穴腔体，主导完成150万标准立方米氢气储存，成功实现我国盐穴大规模储氢工程实践，攻克系列世界级技术难题。http://finance.sina.com.cn/tech/roll/2026-04-28/doc-inhvyzkk8598767.shtml6、#太阳黑子群14425爆发事件##天文探索计划# ｜ #上微博涨知识# ｜#空间天气事件#【 #太阳黑子群14425爆发事件# 】【太阳耀斑爆发事件】++++++++++++++[绿]色警报++++++++++++++太阳黑子群14425在北京时间2026年04月28日06时54分爆发了一个C1.4级小耀斑。http://k.sina.com.cn/article_1808449333_6bcabf3500101cmj2.html7、人类在南美洲的定居，经历“三迁”南美洲是人类定居的最后一个大陆，许多科学家曾认为这一过程相当简单：大约1.5万年前，大多同种族的古人来到这片大陆，适应了在茂密丛林和高原之巅生活，并最终留了下来。然而，一项4月22日发表于《自然》的研究揭示，这些迁徙并不简单。研究团队分析了来自南美洲及其他地区的古代与现代人类基因组，发现至少有3种基因存在差异的人群分布在这片大陆上。其中一些人还携带着从澳大拉西亚祖先那里获得的有利基因。研究人员发现，南美洲的遗传历史与其生态系统一样复杂。图为智利托雷斯德尔佩尼亚的河流。图库版权图片，转载使用可能引发版权纠纷“殖民时代前的遗传多样性大多已丧失。http://k.sina.com.cn/article_5104880035_1304649a301901kz6g.html8、春日飞絮，央企“开方”→春光明媚，草长莺飞。然而，漫天飞舞的杨柳絮却像“春日雪花”一般无孔不入，不仅在头发、衣服上粘得到处都是，更是让人喷嚏连天、眼红鼻塞，堪称过敏体质的“魔咒”。为了让你放心呼吸，中央企业开出了科技和生态两剂“良方”——科技“药方”：新型材料锁住飞絮“杨花榆荚无才思，惟解漫天作雪飞。”古人笔下的诗意，到了现代过敏人群这里却成了“会呼吸的痛”。连日来，在北京市大兴区瀛海镇、清源街道辖区道路两旁和念坛公园内，园林工作者们用喷洒设施对雌株杨树和公园街道地面上的杨絮进行大面积喷淋作业。http://finance.sina.com.cn/wm/2026-04-28/doc-inhvyzks7410665.shtml9、一周内又有3款新药在国内申报上市（来源：药财社）来源 | 北京药研汇2026年，在中国医药创新经过多年积累后，行业开始进入成果落地的“丰收季”，越来越多重磅新药也迈入了上市阶段。据悉，在本周就又有3款新药上市申请获受理。随着越来越多新药陆续进入审批尾声，2026年注定将成为中国医药创新的“大年”。▲关注药财社聚焦医药界▲2026年4月22日，华东医药官方发布，其全资子公司华东医药（杭州）有限公司独家商业化产品CXG87（布地奈德福莫特罗吸入粉雾剂（IV）胶囊型）的药品注册上市许可申请获国家NMPA受理，申报适应症为：用于治疗哮喘，以达到哮喘的总体控制。http://k.sina.com.cn/article_5953740931_162dee083067033zrm.html10、珍稀白头蝰首次现身梵净山当地蛇类增至43种转自：贵州日报本报讯（记者杨阳萌）近日，梵净山发现一种白头蝰属的蛇类，经贵州科学院生物研究所副研究员、蛇类专家吕敬才鉴定，该蛇类确认为白头蝰，系该物种在梵净山国家级自然保护区的首次记录。至此，梵净山蛇类物种数量正式增至43种。由于其种群数量稀少，2015年，白头蝰被《中国生物多样性红色名录》评定为“易危”等级，属于需要重点保护的珍稀蛇类物种。吕敬才表示，白头蝰对研究管牙类毒蛇的起源与演化具有重要科学价值。此次在梵净山首次发现该物种，不仅丰富了当地蛇类物种多样性，也进一步彰显了梵净山作为“物种基因库”的独特生态价值，为后续开展珍稀爬行动物保护、科研监测工作提供了重要参考。http://finance.sina.com.cn/jjxw/2026-04-28/doc-inhvyvas8722929.shtml11、揭秘“基因编辑低过敏猫”背后团队据世界卫生组织国际免疫学会联合会全球过敏性疾病流行报告，全球近10%人群存在猫特异性过敏致敏反应。今年初，扬州大学兽医学院副教授袁玉国团队通过基因编辑技术，成功培育出一对雌雄低过敏猫“安安”“康康”，这于喜欢猫却又担心过敏的爱猫人来说，无疑是莫大利好消息。4月25日，“安安”“康康”迎来“百露”，记者走进扬大兽医学院动物基因工程实验室，揭开“基因编辑低过敏猫”科研团队的神秘面纱——总设计师：是“指挥官”也是“战斗员” 标签：袁玉国副教授阳光房里铺着崭新的软垫，墙上挂着“100 DAYS”气球，“安安”“康康”正互相追逐。这场特殊的百日庆典，见证着两只萌猫的健康成长。http://finance.sina.com.cn/wm/2026-04-28/doc-inhvyvas8724886.shtml12、足不出京，用AI给光伏电站“测温”（来源：千龙网）足不出京，利用AI（人工智能）技术就能为光伏电站“测温”。昨天（27日），中国科学院青藏高原研究所科研团队介绍，利用高分辨率数据集与机器学习模型开展的评估有结论了：我国光伏电站对地表温度的日平均增温效应仅为0.01摄氏度，在全国区域尺度上几乎可以忽略不计。这为推动我国太阳能资源的可持续利用，提供了重要的科学依据。《2025中国光伏建设进展报告》显示，截至当年7月，全国光伏累计装机规模突破11亿千瓦，较上年同期增长50.8%。有人提出质疑，这些被比喻为“小太阳”的电站，是否会引起地表温度的显著变化。“地表温度是衡量地表能量平衡的重要指标。http://finance.sina.com.cn/jjxw/2026-04-28/doc-inhvyvar1948612.shtml13、快来吸!中国首只克隆猫今日满月　与原体同名叫“大蒜”_新闻中心2019年8月21日，我国首只克隆猫“大蒜”满月。（图片来源：IC photo）　　8月19日，“克隆猫新闻发布会”在京举行。大蒜是一只可爱的英国短毛猫，于2019年7月21日出生，目前健康状况良好。大蒜的克隆原体与它同名，是一只2岁半的雄性英短。中国农业大学动物医学院教授称，克隆猫较困难、操作繁琐，此次标志我国在克隆领域迈进一大步。http://k.sina.com.cn/article_7857201856_1d45362c001904spdo.html14、超大規模宇宙學模擬項目“千衍”首批成果發布--經濟·科技--人民網記者4月23日從中國科學院國家天文台獲悉，由我國科研人員領銜的國際研究團隊近日發布超大規模宇宙學模擬項目“千衍”首批成果，成功在約120億光年尺度的宇宙空間內，高精度再現宇宙百億年演化歷程，為探索宇宙奧秘提供高精度“數字導引圖”。“千衍”模擬使用約4.2萬億個暗物質粒子，通過N體模擬技術精准追蹤暗物質聚集與宇宙結構形成過程，完整輸出100個宇宙演化階段快照。項目還可生成星系光度、光譜、虛擬觀測圖像等信息，將為研究暗物質、暗能量等基礎宇宙學問題，以及檢驗標准宇宙學模型提供關鍵支撐。http://k.sina.com.cn/article_7857201856_1d45362c001904sqxg.html15、用微生物发酵生产体系破局山梨酸“天然来源”本报讯（记者李珂）大家平常吃的面包、喝的果汁，很可能都含有一种叫山梨酸的防腐剂，它能有效抑菌，是全球公认最安全的食品添加剂之一。你可能不知道：目前几乎所有的山梨酸，都是用石油衍生的化学原料合成的——资源不可再生，生产过程也不够环保。更关键的是，这种“化学合成”身份让它难以满足消费者对“天然来源”成分的期待。如今，这一局面被福建师范大学团队成功打破。记者27日获悉，福建师范大学生命科学学院李力教授团队等在国际顶级期刊《自然·通讯》上发表突破性成果：他们成功通过酿酒酵母“酿造”出了高产量的山梨酸。研究的第一步，是找到微生物制造山梨酸的“天然蓝图”。http://finance.sina.com.cn/jjxw/2026-04-28/doc-inhvyzkq8610073.shtml16、“自带开关”的CAR-T疗法一期临床告捷（来源：财联社）财联社4月28日电，一项创新的“自带开关”CAR-T细胞疗法早期临床数据公布，为多种难治性实体肿瘤患者带来了曙光。美国宾夕法尼亚大学团队日前在美国癌症研究协会（AACR）年会上报告其一期临床试验结果告捷：名为KIR-CAR的新型细胞疗法首次进入人体试验，在晚期卵巢癌、间皮瘤和胆管癌患者中显示出良好的安全性和积极的疗效信号。这标志着人们在攻克实体肿瘤的道路上又迈出了关键一步。http://k.sina.com.cn/article_5953740931_162dee083067033zom.html17、“翼”起守护 | 南京市十大常见鸟类②南京优良的自然生态环境，特别是丰富的湿地和森林资源，为鸟类提供了理想的栖息地，全市鸟类多样性极为丰富，截至2025年3月，累计记录鸟类达389种，其中国家一级重点保护鸟类15种、国家二级重点保护鸟类76种。那么，南京最常见的鸟类有哪些呢？小桐妹为大家选取了我市十大常见鸟类，一起来看看吧~灰喜鹊灰喜鹊（Cyanopica cyanus）属于雀形目、鸦科，俗称“山蛮子”，为我国“三有”动物。成鸟头部顶羽光泽黑，喉部白色，背部及腹部为淡灰棕色，翅膀与尾呈现独特的天蓝色，尾较长。在南京常见于公园、居民区、林地和郊区等生境，叫声嘈杂，常集小群活动，性情凶猛。http://k.sina.com.cn/article_7857201856_1d45362c001904spmq.html

2026-04-28

·BioSpace

BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca’s single-inhaler fixed-dose triple therapy compared with inhaled dual therapy Approval is second indication for BREZTRI beyond COPD WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s fixed-dose triple-combination therapy BREZTRI Aerosphere ® (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) has been approved in the US for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older. BREZTRI is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines with a long-acting muscarinic antagonist (LAMA). BREZTRI (320/18/9.6μg) was approved in the US in 2020 to treat adults with chronic obstructive pulmonary disease (COPD) and was prescribed to more than 6.8 million patients globally in 2025. 1,2 The approval by the US Food and Drug Administration (FDA) was based on efficacy and safety data from the Phase III KALOS and LOGOS trials investigating BREZTRI in a broad population consisting of patients with asthma, with or without a recent asthma exacerbation. 3 In these trials, BREZTRI demonstrated a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled ICS/LABA. 3 In a key secondary endpoint, BREZTRI also demonstrated a rapid onset of action with a significant improvement from baseline in lung function within five minutes after the first dose. 3 BREZTRI is a maintenance therapy and is not used to relieve sudden breathing problems and will not replace a rescue inhaler. Njira Lugogo, MD, Clinical Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, said: “Despite the availability of dual maintenance therapy, many patients are still at risk for exacerbations and experience daily breathing difficulties, reduced lung function and the ongoing fear of worsening symptoms. The FDA approval of BREZTRI as the only maintenance triple therapy for people with asthma 12 years of age and older marks a pivotal moment in helping those living with this debilitating disease breathe better, sooner.” Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: “As the fastest growing fixed-dose triple-combination therapy in COPD, BREZTRI is already improving outcomes for people suffering with COPD, and we are proud to extend its benefits to asthma patients. The FDA’s approval of BREZTRI in asthma demonstrates how our innovative science continues to bring new solutions for patients with respiratory diseases.” There are 27 million people living with asthma in the US, 4 around half of whom continue to be uncontrolled on dual therapies, leading to inflammation and muscle tightening in the airway (bronchoconstriction) that cause wheezing, breathlessness, chest tightness, coughing exacerbations and even death. 5,6 Nearly 10 million asthma attacks still occur each year in the US. 4 Results from KALOS and LOGOS were published in The Lancet Respiratory Medicine in February 2026. 3 There were no new safety or tolerability signals identified for BREZTRI in the trials. 3 BREZTRI is a single-inhaler fixed-dose triple-combination therapy approved for the treatment of COPD in adults in 90 countries worldwide including the US, EU, China and Japan. Regulatory filings for BREZTRI in asthma are currently under review in other major regions including the EU, Japan and China. IMPORTANT SAFETY INFORMATION BREZTRI is contraindicated: For the primary treatment of status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures In patients who have a hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate or product excipients Long-acting beta 2 -adrenergic agonist (LABA) monotherapy for asthma is associated with an increased risk of serious asthma-related events. These findings are considered a class effect of LABA monotherapy. When a LABA is used in a fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS use alone. Available data do not suggest an increased risk of death with use of LABA in patients with COPD BREZTRI should not be initiated in patients with acutely deteriorating COPD or asthma, which may be a life-threatening condition BREZTRI is NOT a rescue inhaler. Do NOT use to relieve acute symptoms; treat with an inhaled short-acting beta 2 -agonist BREZTRI should not be used more often than recommended; at higher doses than recommended; or in combination with LABA-containing medicines, due to risk of overdose. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing budesonide. Advise patients to rinse their mouths with water without swallowing after inhalation Lower respiratory tract infections, including pneumonia, have been reported following ICS. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap Due to possible immunosuppression, potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients Particular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to BREZTRI Hypercorticism and adrenal suppression may occur with regular or very high dosage in susceptible individuals. If such changes occur, consider appropriate therapy Caution should be exercised when considering the coadministration of BREZTRI with long-term ketoconazole and other known strong CYP3A4 Inhibitors. Adverse effects related to increased systemic exposure to budesonide may occur If paradoxical bronchospasm occurs, discontinue BREZTRI immediately and institute alternative therapy Anaphylaxis and other hypersensitivity reactions (eg, angioedema, urticaria or rash) have been reported. Discontinue and consider alternative therapy Use caution in patients with cardiovascular disorders, especially coronary insufficiency, as formoterol fumarate can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles Decreases in bone mineral density have been observed with long-term administration of ICS. Assess initially and periodically thereafter in patients at high risk for decreased bone mineral content Monitor growth in pediatric patients Glaucoma and cataracts may occur with long-term use of ICS. Worsening of narrow-angle glaucoma may occur, so use with caution. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use BREZTRI long term. Instruct patients to contact a healthcare provider immediately if symptoms occur Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if symptoms occur Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis or unusually responsive to sympathomimetic amines Be alert to hypokalemia or hyperglycemia Most common adverse reactions (incidence ≥ 2%) are: COPD: upper respiratory tract infection, pneumonia, back pain, oral candidiasis, influenza, muscle spasms, urinary tract infection, cough, sinusitis, and diarrhea Asthma: nasopharyngitis, pneumonia, and headache BREZTRI should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors and tricyclic antidepressants, as these may potentiate the effect of formoterol fumarate on the cardiovascular system BREZTRI should be administered with caution to patients being treated with: Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects) Adrenergic drugs (may potentiate effects of formoterol fumarate) Xanthine derivatives, steroids, or non-potassium sparing diuretics (may potentiate hypokalemia and/or ECG changes) Beta-blockers (may block bronchodilatory effects of beta-agonists and produce severe bronchospasm) Anticholinergic-containing drugs (may interact additively). Avoid use with BREZTRI Use BREZTRI with caution in patients with hepatic impairment, as budesonide and formoterol fumarate systemic exposure may increase. Patients with severe hepatic disease should be closely monitored INDICATIONS BREZTRI AEROSPHERE 160 mcg/9 mcg/4.8 mcg is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. BREZTRI AEROSPHERE 160 mcg/18 mcg/4.8 mcg is indicated for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older. LIMITATIONS OF USE Not indicated for the relief of acute bronchospasm. Please see full BREZTRI Prescribing Information , including Patient Information . You may report side effects related to AstraZeneca products . Notes Asthma Asthma is a prevalent, chronic respiratory disease affecting as many as 262 million people worldwide, 8 including 27 million in the US. 4 When uncontrolled, inflammation and muscle tightening in the airway (bronchoconstriction) may cause wheezing, breathlessness, chest tightness, coughing, and even death. 5-7 Many patients remain uncontrolled despite the availability of standard of care medicines and continue to experience significant limitations on lung function and reduced quality of life. 6,7 KALOS and LOGOS Phase III trials KALOS and LOGOS were replicate confirmatory, randomised, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials to assess the efficacy and safety of BREZTRI Aerosphere compared with S ymbicort (budesonide/formoterol fumarate, a marketed therapeutic option), PT009 (budesonide/formoterol fumarate in an Aerosphere formulation) and the Symbicort and PT009 treatment groups combined. 3,9,10 KALOS and LOGOS included approximately 4,300 randomised patients. The primary endpoints for the two individual trials were a change from baseline in forced expiratory volume in 1 second (FEV 1 ) area under the curve 0 to 3 hours (AUC 0-3 ) at Week 24 and trough FEV 1 over 12-24 weeks and over 24 weeks. 3,9,10 The primary endpoints and treatment comparisons in the KALOS and LOGOS trials differed according to regulatory submission approaches. In the data package submitted to the US FDA, the primary lung function endpoint was change from baseline in FEV 1 AUC 0-3 at week 24, and the key secondary endpoint was change from baseline in morning pre-dose trough FEV 1 at week 24, compared to PT009. 3 BREZTRI / TRIXEO Aerosphere Budesonide/glycopyrronium/formoterol fumarate or budesonide/glycopyrrolate/formoterol fumarate, is approved under the brand name BREZTRI Aerosphere in Japan, China and the US, and Trixeo Aerosphere in the EU, is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, a LABA, glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), with budesonide, an ICS, and delivered via the Aerosphere pMDI. BREZTRI/TRIXEO Aerosphere is approved to treat adults with COPD in 90 countries worldwide including the US, EU, China, Japan, and was prescribed to more than 6.8 million patients globally in 2025. 2 AstraZeneca in Respiratory & Immunology Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company. AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases. AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca . References AstraZeneca. Breztri Aerosphere approved in the US for the maintenance treatment of COPD. Press Release. 24 July 2020. Available at: . [Last accessed: April 2026]. AstraZeneca. Data On File. REF-325003. Papi A, et al. Budesonide/glycopyrronium/formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin phase 3, randomised, double-blind, double-dummy, parallel-group, multicentre trials. Lancet Respir. Med . 2026. Available at: (25)00457-6/abstract [Last accessed: April 2026]. U.S. Centers for Disease Control and Prevention (CDC). Most Recent Asthma Data. [Online]. Available at: [Last accessed: April 2026]. Fernandes AG, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol . 2014; 40 (4): 364-372. Davis J, et al. Burden of asthma among patients adherent to ICS/LABA: A real-world study. J Asthma . 2019 Mar;56(3):332-340. Buhl R, et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respir Med . 2020 Feb: 162:105859. Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: . [Last accessed: April 2026]. Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) [Online]. Available at: . [Last accessed: April 2026]. Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) [Online]. Available at: [Last accessed: April 2026]. Contacts Media Inquiries Fiona Cookson +1 212 814 3923 US Media Mailbox: usmediateam@astrazeneca.com

100 项与布地奈德福莫特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	布地奈德福莫特罗	R03AK07	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
轻度哮喘	英国	AstraZeneca PLC	2023-03-23
哮喘	澳大利亚	AstraZeneca Pty Ltd.	2002-05-27
慢性阻塞性肺疾病	澳大利亚	AstraZeneca Pty Ltd.	2002-05-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
儿童哮喘	临床3期	法国	AstraZeneca PLC	2021-08-23
慢性哮喘	临床3期	美国	Teva Pharmaceuticals USA, Inc.	2017-01-13
纤毛运动障碍	临床3期	美国	AstraZeneca PLC	2007-01-01
新生儿败血症	临床3期	丹麦	AstraZeneca PLC	2005-05-01
新生儿败血症	临床3期	法国	AstraZeneca PLC	2005-05-01
新生儿败血症	临床3期	德国	AstraZeneca PLC	2005-05-01
新生儿败血症	临床3期	西班牙	AstraZeneca PLC	2005-05-01
新生儿败血症	临床3期	瑞典	AstraZeneca PLC	2005-05-01
新生儿败血症	临床3期	英国	AstraZeneca PLC	2005-05-01
气道病变	临床3期	瑞典	AstraZeneca PLC	2004-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05755906 (LITHOS, CTgov)	临床3期	哮喘	374	BFF MDI (BFF MDI 160/9.6 μg)	製選選齋鹹網構構鬱願(選願願夢窪鑰願壓憲獵) = 壓製膚選鏇蓋觸衊餘襯築顧鏇繭艱淵網廠衊範 (鹹製鬱鑰獵網願製網選, 0.0235) 更多	-	2026-01-28
				BD MDI (BD MDI 160 μg)	製選選齋鹹網構構鬱願(選願願夢窪鑰願壓憲獵) = 醖簾選襯蓋構製艱壓壓築顧鏇繭艱淵網廠衊範 (鹹製鬱鑰獵網願製網選, 0.0241) 更多
NCT06429475 (PACTR202502547023775, Pubmed \| BMJ Open Respir Res)	临床3期	哮喘	360	Budesonide/formoterol inhaler	膚蓋廠積顧遞窪窪築壓(醖選夢蓋範醖獵觸鏇願) = 廠襯糧鏇壓顧積製膚選鏇衊窪鑰獵鏇衊鏇觸鹽 (鏇遞糧構廠窪網鹽獵選 )	积极	2025-11-01
				Standard of care (ICS and SABA)	膚蓋廠積顧遞窪窪築壓(醖選夢蓋範醖獵觸鏇願) = 憲衊醖鏇鏇襯構糧製鬱鏇衊窪鑰獵鏇衊鏇觸鹽 (鏇遞糧構廠窪網鹽獵選 )
NCT01167010 (UNIK, CTgov)	临床3期	哮喘 \| 持续性哮喘	552	Formoterol/Budesonide (Formoterol/Budesonide)	製願餘膚膚艱蓋範蓋壓(艱遞築壓醖夢願淵醖範) = 選艱衊衊繭網衊網繭觸網構獵壓顧醖憲鬱鏇鏇 (鹹醖觸鏇蓋鬱鬱膚窪網, 0.79) 更多	-	2025-05-01
				Alenia (Alenia)	製願餘膚膚艱蓋範蓋壓(艱遞築壓醖夢願淵醖範) = 衊鬱艱衊鹹夢窪憲鹽網網構獵壓顧醖憲鬱鏇鏇 (鹹醖觸鏇蓋鬱鬱膚窪網, 0.77) 更多
NCT03924635 (CTgov)	临床4期	哮喘 \| 气道病变	42	salbutamol+SYMBICORT (SYMBICORT as Maintenance and Reliever Treatment)	簾製鹽艱顧鏇願膚顧艱(艱夢糧齋廠衊遞簾蓋壓) = 艱積糧艱襯艱鹹淵憲鹽衊積糧鬱廠醖鹹鬱積繭 (襯遞構糧糧鹽醖構膚廠, 簾蓋築範獵齋鬱餘鏇遞 ~ 淵構壓顧顧餘鏇憲襯鏇) 更多	-	2025-01-22
				salbutamol+SYMBICORT (SYMBICORT as Maintenance, Salbutamol as Reliever Treatment)	簾製鹽艱顧鏇願膚顧艱(艱夢糧齋廠衊遞簾蓋壓) = 鏇鏇範壓觸醖齋觸膚齋衊積糧鬱廠醖鹹鬱積繭 (襯遞構糧糧鹽醖構膚廠, 鬱鑰齋壓艱餘願鏇夢襯 ~ 繭壓願築製糧廠簾窪廠) 更多
NCT04159519 (SHAMAL, CTgov)	临床4期	哮喘 \| 嗜酸性粒细胞性哮喘	170	salbutamol+Symbicort+benralizumab (Treatment Reduction)	網構糧壓衊獵鬱鬱衊膚 = 衊餘積餘鑰顧繭襯廠構範襯積淵襯繭獵觸鑰蓋 (遞範顧構鑰鹹積遞衊窪, 遞觸蓋餘鑰糧構鬱顧壓 ~ 壓淵壓鹹蓋餘鹽鏇鹹窪) 更多	-	2025-01-09
				salbutamol+Symbicort+benralizumab (Reference)	蓋網醖齋壓顧鬱鹽獵醖(齋憲獵網鬱艱壓鑰願淵) = 製襯觸範廠遞醖製齋簾鏇獵願顧憲艱襯鏇淵繭 (糧醖顧鑰窪構淵鹹繭壓, 0.0677) 更多
CTR20180475 (CTR20180475, Pubmed \| COPD)	临床3期	慢性阻塞性肺疾病	750	Beclometasone Dipropionate/Formoterol Fumarate	鹽築簾鬱鬱積蓋蓋簾廠(廠築構積觸製醖簾壓糧) = 窪顧齋顧選襯獵膚襯鏇鏇窪製夢膚構壓觸製構 (顧夢窪鹽顧窪襯築鹽鹹, -0.025 ~ 0.022)	积极	2024-12-31
				Budesonide/Formoterol Fumarate	鹽築簾鬱鬱積蓋蓋簾廠(廠築構積觸製醖簾壓糧) = 糧鏇艱鏇鑰廠齋鑰衊蓋鏇窪製夢膚構壓觸製構 (顧夢窪鹽顧窪襯築鹽鹹, -0.024 ~ 0.022)
ATS2024	N/A	慢性阻塞性肺疾病	-	Fluticasone Furoate/Umeclidinium/Vilanterol	網獵願繭醖鹹築範蓋顧(構鹽餘選鬱醖憲鑰繭願) = 願鹽膚鹽願艱淵淵鹽顧顧醖餘遞製獵鑰遞膚窪 (憲襯鬱遞醖網鑰鹹鹽鹽 )	-	2024-05-19
				Budesonide/Formoterol	網獵願繭醖鹹築範蓋顧(構鹽餘選鬱醖憲鑰繭願) = 積鹽憲醖醖膚鹽遞願鬱顧醖餘遞製獵鑰遞膚窪 (憲襯鬱遞醖網鑰鹹鹽鹽 )
NCT01803555 (CTgov)	临床3期	持续性哮喘	605	SYMBICORT placebo+Budesonide/Formoterol SPIROMAX® (BF Spiromax)	糧鬱襯鏇鑰範衊積顧齋(餘鹽範顧襯糧艱築醖鬱) = 壓製醖繭鏇鬱壓鹽齋襯夢襯襯簾製膚顧醖齋憲 (鏇憲醖製鬱膚蓋鬱襯願, 2.754) 更多	-	2023-12-08
				SPIROMAX Placebo+SYMBICORT® TURBOHALER® (Symbicort Turbohaler)	糧鬱襯鏇鑰範衊積顧齋(餘鹽範顧襯糧艱築醖鬱) = 廠廠範憲遞遞築鏇觸蓋夢襯襯簾製膚顧醖齋憲 (鏇憲醖製鬱膚蓋鬱襯願, 2.745) 更多
NCT02766608 (TELOS, FDA) 人工标引	临床3期	慢性阻塞性肺疾病	-	SYMBICORT AEROSPHERE	餘淵襯襯窪淵憲簾憲鏇(糧顧範淵廠鏇醖鑰糧獵): Difference = 157 (95% CI, 121 ~ 193) 更多	积极	2023-04-28
				budesonide
NCT02727660 (SOPHOS, FDA) 人工标引	临床3期	慢性阻塞性肺疾病	-	SYMBICORT AEROSPHERE	廠積窪築築觸糧遞窪願(鑰膚獵鬱襯糧窪選簾艱) = Adverse reactions occurred at an incidence of at least 2% and more frequently in SYMBICORT AEROSPHERE 320 mcg/9.6 mcg than in FF MDI 9.6 mcg. 鬱鏇壓獵襯繭積衊夢膚 (積鬱鏇獵襯廠襯繭選願 ) 更多	积极	2023-04-28
				formoterol fumarate